The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: a low-value intervention?

The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: a low-value intervention? Journal Article uri icon

Overview

Link to Article

10.1016/j.gore.2015.06.009

authors

Cohn, D. E.

Shimp, W. S. HealthPartners Author

publication date

2015

published in

Gynecologic oncology reports Journal

Research

keywords

Drugs and Drug Therapy

Economics

Ovarian Cancer

Additional Document Info

volume